DRAMATIC (Duration Randomized Anti-MDR-TB And Tailored Intervention Clinical) Trial is a multicenter, randomized, partially blinded, four-arm, phase 2 trial that will examine an injectable- and pyrazinamide-sparing regimen of bedaquiline, delamanid, levofloxacin, linezolid, and clofazimine for treatment of MDR-TB. Participants will be randomized (1:1:1:1) to the following four investigational arms. All arms receive the same investigational oral regimen of levofloxacin, bedaquiline, linezolid, delamanid, and clofazimine; each arm represents a different the total duration of treatment, specifically 16 weeks (112 doses), 24 weeks (168 doses), 32 weeks (224 doses) or 40 weeks (280 doses).